Replies to post #29300 on Univec Inc (UNVC)

[Almost A Myth]

KW, I'm thinking the same thing. I know I've said this a couple of times, but having Merck enter this equation at this time is very very intriguing!!!!

Why would one of the biggest pharmaceutical companies in the world be eying Dr Dalton?

Here's my personal opinion (!!!!) of what's transpiring:

AGRiMED took on Dr Dalton and Univec because of the Dr's experience in the pharma industry. The patch JV is an example of how the producer (AGRiMED) is turning to someone who has pharma experience for guidance (Dalton). Being vice-chairman at AGRiMED, Dalton now has partial control of operations at AGRiMED. So I think Dalton is quietly working with the chemists there to develop a CBD based drug that will be eligible for FDA approval. In the meantime, Merck is looking at one of its major rivals (GW Pharma) be the first to enjoy FDA approval of a CBD drug. This has Merck on a fast track to get their own CBD drug to market. So who do they look to for a jump start on this process? The best in the industry. As we know AGRiMED had the highest scores of all 12 of the PA MMJ license applicants, and their team of executives have extremely impressive resumes.

So what happens to Univec while all of this is going on? Considering that Dalton is a major shareholder of UNVC, AGRiMED will do everything in its power to get the shell in order and execute a merger, possibly (probably) with Sativeo involved as a third merging entity. That will set up a powerhouse of a publicly traded company, increase the PPS exponentially, reward Dalton for his work, and make it an attractive takeover candidate for a big pharmaceutical company looking to get a jump on production of a CBD drug. Hmmmm, who do we know who fits that description? I'll give you a hint, their stock price is $70+ per share.

Lets say for a minute that Merck will never get involved with AGRiMED. AGRiMED, being a relatively new company, will need to come up with their own funding for the arduous and expensive FDA approval process for their CBD drug, so they will NEED TO GO PUBLIC to raise that kind of capital.

I don't know about the products and testing that have been mentioned on this board, because until I see proof for myself, IMO that's all speculation. But it's neither here nor there anyway when we look at all of the 100% verifiable information that's been uncovered already.

Back taxes, back wages, and the SOS situation are all insignificant when we look at the returns that $UNVC will yield when the problems are ironed out and the shell is wrapped around the new entity. If those hurdles were insurmountable, I'm sure Dalton would be dumping his stock into every uptick we get. But Dalton is not selling.